VSTM

Verastem has given shareholders a rough ride over the longer term, yet the share price has moved sharply enough at times to keep the story alive.

Verastem Oncology reported initial multi tumor data from its TARGET D 101 Phase 1/2 trial, showing robust clinical activity and a favorable safety and tolerability profile for VS-7375 across KRAS G12D-mutated pancreatic, colorectal and lung cancers, and…

Verastem (VSTM) is in focus after releasing detailed TARGET-D 101 trial data for VS-7375 in KRAS G12D-mutated tumors and then quickly following up with a roughly US$250 million follow-on equity raise.

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose.

Verastem's (VSTM) G12D drug showed promising efficacy in pancreatic cancer, while its shares remain

Verastem is advancing the KRAS inhibitor into later stage studies following the data readout.

Verastem (NASDAQ:VSTM) presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer.

Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.

Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.

Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.

Verastem reported positive results from its ongoing Phase 1/2 trial involving patients with advanced cancers carrying the KRAS G12D mutation.